VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
- 30 September 2010
- journal article
- research article
- Published by Elsevier BV in Lung Cancer
- Vol. 69 (3), 337-340
- https://doi.org/10.1016/j.lungcan.2009.11.019
Abstract
No abstract availableKeywords
Funding Information
- Vanderbilt Lung Cancer SPORE (P50 CA-90949)
- SPECS (UO1 CA114771)
This publication has 10 references indexed in Scilit:
- Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing RegimenJournal of Thoracic Oncology, 2009
- Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group StudyClinical Cancer Research, 2008
- Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of Seven Randomized Clinical TrialsJournal of Thoracic Oncology, 2007
- Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional StudyJNCI Journal of the National Cancer Institute, 2007
- Bevacizumab in the treatment of non-small-cell lung cancerOncogene, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Angiogenesis and Lung Cancer: Prognostic and Therapeutic ImplicationsJournal of Clinical Oncology, 2005
- Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005